Vaccine therapy of B cell malignancies: different strategies for a novel approach.
This review deals with the theoretical principles and experimental results of immunotherapy for B cell malignancies, namely for non-Hodgkin lymphomas (NHLs) and multiple myeloma. Its focus is the use of vaccines in clinical practice with particular emphasis on the most recent developments and therapeutic opportunities arising from combination therapies. Previous studies will be reviewed and the present status of vaccine technology summarized.
Liso
A
A
University of Perugia, Institute of Hematology, Italy. arliso@yahoo.com
Benedetti
R
R
Flenghi
L
L
Falini
B
B
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001402:B-Lymphocytes / Q000473:pathology*; D019496:Cancer Vaccines / Q000627:therapeutic use*; D019337:Hematologic Neoplasms / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods / Q000639:trends; D015448:Leukemia, B-Cell / Q000628:therapy; D016393:Lymphoma, B-Cell / Q000628:therapy; D009101:Multiple Myeloma / Q000628:therapy
D019496:Cancer Vaccines